NOVARTIS

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Clinical Trials

A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure

Phase 2

Completed

Conditions: Chronic Heart Failure

First Posted Date: 2006-02-20

Last Posted Date: 2011-06-08

Lead Sponsor: Novartis

Target Recruit Count: 160

Registration Number: NCT00294086

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Phase 2

Terminated

Conditions: Recurrent Glioblastoma Multiforme (GBM)

Interventions: Drug: Imatinib tablets
Drug: Hydroxyurea capsules

First Posted Date: 2006-02-13

Last Posted Date: 2011-05-16

Lead Sponsor: Novartis

Target Recruit Count: 231

Registration Number: NCT00290771

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Phase 3

Completed

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Drug: Fingolimod 1.25 mg
Drug: Fingolimod 0.5 mg
Drug: Placebo

First Posted Date: 2006-02-10

Last Posted Date: 2012-04-11

Lead Sponsor: Novartis

Target Recruit Count: 1272

Registration Number: NCT00289978

Locations: 🇹🇷
Gaziantep University School of Medicine, Neurology Department, Gaziantep, Turkey
🇦🇺
The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
🇬🇷
Athens Naval Hospital, Neurology Department, Athens, Greece

and more 95 locations

Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration

Phase 2

Completed

Conditions: Age-Related Macular Degeneration (ARMD)

First Posted Date: 2006-02-08

Last Posted Date: 2008-06-19

Lead Sponsor: Novartis

Registration Number: NCT00288561

Locations: 🇨🇭
Novartis, Basel, Switzerland

Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients

Phase 3

Completed

Conditions: Kidney Diseases

Interventions: Drug: Enteric-coated mycophenolate sodium (EC-MPS)
Drug: Tacrolimus
Drug: Corticosteroids

First Posted Date: 2006-02-01

Last Posted Date: 2011-05-02

Lead Sponsor: Novartis

Target Recruit Count: 94

Registration Number: NCT00284934

Locations: 🇨🇭
Novartis, Basel, Switzerland

Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids

Phase 4

Completed

Conditions: Adverse Effects
Kidney Transplantation

Interventions: Drug: basiliximab
Drug: MMF/EC-MPS
Drug: Corticosteroids

First Posted Date: 2006-02-01

Last Posted Date: 2017-03-29

Lead Sponsor: Novartis

Target Recruit Count: 7

Registration Number: NCT00284947

Locations: 🇨🇭
Novartis, Basel, Switzerland

Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Phase 1

Completed

Conditions: Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)

Interventions: Drug: Ranibizumab

First Posted Date: 2006-01-31

Last Posted Date: 2011-02-24

Lead Sponsor: Novartis

Target Recruit Count: 88

Registration Number: NCT00284089

Locations: 🇯🇵
Novartis, Tokyo, Japan

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement

Phase 2

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Ranibizumab 0.3 mg
Drug: Sham injection
Drug: Ranibizumab 0.5 mg

First Posted Date: 2006-01-31

Last Posted Date: 2011-02-24

Lead Sponsor: Novartis

Target Recruit Count: 151

Registration Number: NCT00284050

Locations: 🇨🇭
Novartis, Basel, Switzerland

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2006-01-23

Last Posted Date: 2010-11-09

Lead Sponsor: Novartis

Target Recruit Count: 648

Registration Number: NCT00280540

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Valsartan/Hydrochlorothiazide
Drug: HCTZ

First Posted Date: 2006-01-16

Last Posted Date: 2011-06-07

Lead Sponsor: Novartis

Target Recruit Count: 300

Registration Number: NCT00277472

Locations: 🇺🇸
Novartis, East Hanover, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy